enGene Therapeutics Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- enGene Therapeutics Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-07-31 was $23.00K, a 25.81% decline year-over-year.
- enGene Therapeutics Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-04-30 was $3.00K, a 98.50% decline year-over-year.
- enGene Therapeutics Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-01-31 was $277.00K, a 27600.00% increase year-over-year.
- enGene Therapeutics Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-07-31 was $31.00K, a 39.22% decline year-over-year.
- enGene Therapeutics Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $2.22M, a 1867.26% increase from fiscal 2024.
- enGene Therapeutics Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $113.00K, a 156.82% increase from fiscal 2023.
- enGene Therapeutics Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $44.00K, a 528.57% increase from fiscal 2022.
- enGene Therapeutics Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $7.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-07-31 | $23.00K 10-Q · filed 2026-09-08 | |
| 2026-04-30 | $3.00K 10-Q · filed 2026-09-08 | |
| 2026-01-31 | $277.00K 10-Q · filed 2026-09-08 | |
| 2025-10-31 | $2.22M 10-K · filed 2025-12-22 | |
| 2025-07-31 | $31.00K 10-Q · filed 2026-09-08 | |
| 2025-04-30 | $200.00K 10-Q · filed 2026-09-08 | |
| 2025-01-31 | $1.00K 10-Q · filed 2026-09-08 | |
| 2024-10-31 | $113.00K 10-K · filed 2025-12-22 | |
| 2024-07-31 | $51.00K 10-Q · filed 2025-09-11 | |
| 2024-04-30 | $51.00K 10-Q · filed 2025-09-11 | |
| 2023-10-31 | $44.00K 10-K · filed 2024-12-19 | |
| 2023-04-30 | $17.00K 10-Q · filed 2024-09-10 | |
| 2022-10-31 | $7.00K 10-K · filed 2024-01-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |